Table 2.
Multivariable differences-in-differences quantile regression analyzing change in copayment amounts associated with parity law enactment.
| Change Associated with Parity Laws | ||||
|---|---|---|---|---|
| Drug | Baseline Monthly Copayment, $ |
Estimate, $ | (95% CI) | P |
| Anastrozole | ||||
| 25th percentile | 10.00 | −4.39 | (−4.52 to −4.26) | <0.001 |
| 50th percentile | 10.95 | 0.00 | (--to --) | -- |
| 75th percentile | 25.30 | 0.00 | (--to --) | -- |
| Exemestane | ||||
| 25th percentile | 10.63 | −3.08 | (−4.80 to −1.35) | <0.001 |
| 50th percentile | 31.62 | −10.25 | (−12.61 to −7.89) | <0.001 |
| 75th percentile | 37.94 | 0.00 | (--to --) | -- |
| Letrozole | ||||
| 25th percentile | 10.25 | 7.21 | (7.17 to 7.26) | <0.001 |
| 50th percentile | 21.90 | 0.00 | (--to --) | -- |
| 75th percentile | 37.94 | 0.00 | (--to --) | -- |
| Tamoxifen | ||||
| 25th percentile | 8.18 | −0.21 | (−0.73 to 0.31) | 0.428 |
| 50th percentile | 10.51 | 0.00 | (--to --) | -- |
| 75th percentile | 11.68 | 0.00 | (--to --) | -- |